Journal
GUT
Volume 65, Issue 11, Pages 1895-1905Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/gutjnl-2015-311292
Keywords
-
Categories
Funding
- Medical Research Council, UK [MR/L002094/1, MR/K001949/1]
- Medical Research Council [MR/L002094/1, MR/L016354/1, MR/K001949/1] Funding Source: researchfish
- MRC [MR/L002094/1, MR/L016354/1, MR/K001949/1] Funding Source: UKRI
Ask authors/readers for more resources
Knowledge of the fundamental epigenetic mechanisms governing gene expression and cellular phenotype are sufficiently advanced that novel insights into the epigenetic control of chronic liver disease are now emerging. Hepatologists are in the process of shedding light on the roles played by DNA methylation, histone/chromatin modifications and non-coding RNAs in specific liver pathologies. Alongside these discoveries are advances in the technologies for the detection and quantification of epigenetic biomarkers, either directly from patient tissue or from body fluids. The premise for this review is to survey the recent advances in the field of liver epigenetics and to explore their potential for translation by industry and clinical hepatologists for the design of novel therapeutics and diagnostic/ prognostic biomarkers. In particular, we present findings in the context of hepatocellular carcinoma, fibrosis and nonalcoholic fatty liver disease, where there is urgent unmet need for new clinical interventions and biomarkers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available